drugset / Trial / NCT00534560

Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

NCT00534560 ↗

Phase 2 Completed 542 enrolled Minster Research Ltd
RandomizedParallel-groupTriple-blindPrevention

Summary

Primary objective: To investigate the efficacy and tolerability of two doses of tonabersat compared to placebo in the prophylaxis of migraine headache and to evaluate the longer term tolerability of tonabersat in an open label extension. Secondary objective(s): To obtain further data on the efficacy and dose response of tonabersat; To extend the safety and tolerability database of tonabersat; To obtain data on the pharmacokinetics of tonabersat.

Timeline

Start
2007-10
Primary completion
2008-11
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tonabersat Small molecule 40 mg Oral
Subject Tonabersat Small molecule 60 mg Oral
Subject Tonabersat Small molecule 80 mg Oral